Updated November 2022
Seasonal administration of palivizumab should be considered for children <24 months of age with bronchopulmonary dysplasia (BPD) / chronic lung disease (CLD) and who have required oxygen within 6 months preceding the RSV season (i.e. June 1st - November 2022), or other pulmonary disorders requiring oxygen therapy (e.g. hypoplastic lung).
Share